Response to comment on ‘Drug‐releasing intravesical floating technology for sequential gemcitabine and docetaxel in non‐muscle‐invasive bladder cancer’
BJU International · 2026-07 · 138 (1) · 171-171
DOI: 10.1111/bju.70271 ↗Kurz gefasst
Leserbrief in der Zeitschrift BJU International, online erschienen am 08.04.2026. Verfasst von Melinda Z Fu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urologic Oncology, Department of Surgical Oncology, Rutgers Cancer Institute, New Brunswick, NJ, USA. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Division of Urologic Oncology, Department of Surgical Oncology, Rutgers Cancer Institute, New Brunswick, NJ, USA.
- Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
- Department of Radiation Oncology, University of Iowa, Iowa City, IA, USA.
- Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
ORCID-Profile: Melinda Z Fu
Zitieren
APA
Fu, M. Z., Packiam, V. T., & Byrne, J. (2026). Response to comment on ‘Drug‐releasing intravesical floating technology for sequential gemcitabine and docetaxel in non‐muscle‐invasive bladder cancer’. BJU International, 138(1), 171-171. https://doi.org/10.1111/bju.70271
Vancouver
Fu MZ, Packiam VT, Byrne J. Response to comment on ‘Drug‐releasing intravesical floating technology for sequential gemcitabine and docetaxel in non‐muscle‐invasive bladder cancer’. BJU International. 2026;138(1):171-171. doi:10.1111/bju.70271
BibTeX
@article{Fu2026,
author = {Fu, Melinda Z and Packiam, Vignesh T and Byrne, James},
title = {Response to comment on ‘Drug‐releasing intravesical floating technology for sequential gemcitabine and docetaxel in non‐muscle‐invasive bladder cancer’},
journal = {BJU International},
year = {2026},
volume = {138},
number = {1},
pages = {171--171},
doi = {10.1111/bju.70271}
}
EUVIMED